Systematic Review: Does Semaglutide Increase Risk of Sudden Vision Loss (NAION)? | Research

The takeaway

A systematic review and meta-analysis critically assesses the emerging evidence linking semaglutide specifically to NAION risk, attempting to clarify a growing safety concern.

Semaglutide-NAION link analyzed
First systematic review and meta-analysis specifically addressing this safety concern

What the researchers found

The systematic review and meta-analysis critically assessed the semaglutide-NAION association, synthesizing all available evidence to quantify the risk.

Why it matters

Semaglutide is one of the most prescribed drugs worldwide. Clear evidence about NAION risk is essential for informed prescribing and patient counseling.

How the study worked

Systematic review and meta-analysis with comprehensive literature search for studies examining semaglutide and NAION.

What this study cannot tell us

Limited by the quality and quantity of available primary studies; NAION is very rare making statistical detection difficult; publication bias possible.

How to read the evidence

Systematic review and meta-analysis — highest evidence synthesis methodology, though limited by available primary data.

When this study was published

Published in 2026, providing timely evidence during peak semaglutide prescribing and safety investigation.

The bigger picture

This represents the scientific community's response to safety signals — systematically evaluating concerning reports to provide evidence-based guidance rather than relying on case reports and media coverage.

Questions still open

Is the NAION risk specific to semaglutide or shared across all GLP-1 drugs?
Could the association be driven by rapid metabolic changes rather than a direct drug effect?

Common questions

Can semaglutide cause blindness?

NAION causes sudden vision loss in one eye and is very rare. This systematic review examines whether semaglutide slightly increases this already-low risk. Even if an association exists, the absolute risk would be very small.

Should I stop taking semaglutide because of NAION concerns?

Don't stop medication without consulting your doctor. This review aims to clarify whether the risk is real and how large it might be. For most patients, the metabolic benefits of semaglutide likely outweigh any small vision risk.

Read the original research

Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 15(1), 100245

View on PubMed ↗Publisher’s paper ↗

Citation

Chen, Kai-Yang; Chan, Hoi-Chun; Chan, Chi-Ming. (2026). Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 15(1), 100245. https://doi.org/10.1016/j.apjo.2025.100245